2026

– July –

17 July 2026  Why the World’s Smartest Acquisitions Are No Longer About Buying Companies

26 July 2026 The Proof-of-Concept Premium: Why Biotech’s 2026 Boom Is a Correction, Not a Bubble

– August –

07 August 2026  The 5 Types of Chinese Assets Foreign Investors Are Scrambling to Acquire in 2026: A Structural Shift from “Cost Arbitrage” to “Technology Premium”

13 August 2026  China Is No Longer Just the World’s Factory. It Wants to Supply the Factories Too

19 August 2026  The Niu Lai Lesson: What a Hand-Made Box-Office Surprise Teaches Corporate Dealmakers About Real Options

26 August 2026  Why Big Pharma Is Buying Time: The New Economics of Biotech M&A

– September –

4 September 2026  Eli Lilly’s $2.875 Billion Merida Bet: Why Big Pharma Is Buying Platforms, Not Just Pipelines